Article Details

COVID player and Pfizer-partnered Valneva eyes $100M Nasdaq IPO

Retrieved on: 2021-04-12 14:37:30

Tags for this article:

Click the tags to see associated articles and topics

COVID player and Pfizer-partnered Valneva eyes $100M Nasdaq IPO. View article details on hiswai:

Excerpt

The company also has a phase 2 Lyme disease vaccine candidate called VLA15, which is part of a $308 million R&D deal penned with Pfizer last year ...

Article found on: www.fiercebiotech.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo